{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:33:54Z","timestamp":1774701234693,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jtct.2024.04.016","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T15:47:56Z","timestamp":1713887276000},"page":"683.e1-683.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDmut+ Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada"],"prefix":"10.1016","volume":"30","author":[{"given":"Bhavik J.","family":"Pandya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1341-4424","authenticated-orcid":false,"given":"Linda J.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-6843","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maelys","family":"Touya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Spalding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston","family":"Kuperman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3812-7301","authenticated-orcid":false,"given":"Christopher","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.04.016_bib0001","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/CMAR.S242479","article-title":"Genetic characterization and risk stratification of acute myeloid leukemia","volume":"12","author":"Pourrajab","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jtct.2024.04.016_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0003","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/sj.leu.2403838","article-title":"Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis","volume":"19","author":"Yanada","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.04.016_bib0004","article-title":"Hypomethylating agent-based combination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia","volume":"11","author":"Ciotti","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clml.2019.04.005","article-title":"Allogeneic stem cell transplantation in patients with FLT3-ITD mutated AML: transplantation in CR1 is the decisive factor for good outcome","volume":"19","author":"Jindra","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2024.04.016_bib0006","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2991\/chi.d.190310.001","article-title":"Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia: in vivo T-cell depletion and posttransplant sorafenib maintenance improve survival. A retrospective acute leukemia working party-European Society for Blood and Marrow Transplant","volume":"1","author":"Bazarbachi","year":"2019","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.jtct.2024.04.016_bib0007","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/s41375-023-01994-x","article-title":"FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML","volume":"37","author":"Othman","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.04.016_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101246","article-title":"Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?","volume":"34","author":"Levis","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0009","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","article-title":"A new Leukemia Prognostic Scoring System for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study","volume":"25","author":"Chevallier","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.04.016_bib0010","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","article-title":"Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review","volume":"97","author":"Meg\u00edas-Vericat","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0011","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0012","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.04.016_bib0013","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bmt.2015.170","article-title":"FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML","volume":"51","author":"Song","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.04.016_bib0014","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1002\/cncr.30140","article-title":"Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis","volume":"122","author":"Deol","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2024.04.016_bib0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0016","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","article-title":"An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape","volume":"25","author":"Bystrom","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtct.2024.04.016_bib0017","unstructured":"CIBMTR. 2022 Annual Report. Accessed 24 August, 2023. https:\/\/cibmtr.org\/Files\/Administrative-Reports\/Annual-Reports\/2022-Annual-Report-PRINT.pdf"},{"key":"10.1016\/j.jtct.2024.04.016_bib0018","unstructured":"CIBMTR. Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries, Version 9.1. Accessed 24 August, 2023. https:\/\/cibmtr.org\/Files\/Protocols-and-Consent-Forms\/Research-Database\/Protocol.pdf"},{"key":"10.1016\/j.jtct.2024.04.016_bib0019","unstructured":"ClinicalTrials.gov. A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3\/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) (NCT02997202). Accessed 24 August, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02997202"},{"key":"10.1016\/j.jtct.2024.04.016_bib0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.04.016_bib0021","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/leu.2017.42","article-title":"Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis","volume":"31","author":"Ustun","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.04.016_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial","volume":"13","author":"Bornh\u00e4user","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0023","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0024","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0025","doi-asserted-by":"crossref","first-page":"483.e481","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.04.016_bib0026","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41409-023-02150-w","article-title":"Comparison of fludarabine\/melphalan (FluMel) with fludarabine\/melphalan\/BCNU or thiotepa (FBM\/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a registry study on behalf of the EBMT acut","volume":"59","author":"Duque-Afonso","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.04.016_bib0027","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-022-01865-6","article-title":"Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis","volume":"58","author":"Luo","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.04.016_bib0028","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41409-021-01502-8","article-title":"Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. a retrospective analysis from the EBMT","volume":"57","author":"Penack","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.04.016_bib0029","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00277-021-04661-2","article-title":"The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia","volume":"100","author":"Yanada","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ajh.23443","article-title":"The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation","volume":"88","author":"Mo","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0031","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.04.016_bib0032","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","article-title":"HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age","volume":"6","author":"Ambinder","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.04.016_bib0033","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ejh.13692","article-title":"Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: real-world treatment patterns and outcomes","volume":"107","author":"Griffin","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0034","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3\u2013internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0035","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.14260","article-title":"Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission","volume":"175","author":"Brunner","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0036","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.04.016_bib0037","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.04.016_bib0038","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2023-177929","article-title":"Post-hoc analysis of measurable residual disease from BMT-CTN 1506\/Morpho: FLT3-ITD variant allele frequency and survival are highly correlated","volume":"142","author":"Levis","year":"2023","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724003695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724003695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T06:54:46Z","timestamp":1719989686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724003695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2666636724003695"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.04.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDmut+ Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}